BSI-721 / Biosion - LARVOL DELTA

Development and preclinical activity of BSI-721, a novel antibody-drug conjugate (ADC) targeting cadherin 17 (CDH17) in gastrointestinal cancers (AACR 2025) - "These data highlight the potential of BSI-721 as an effective targeted therapy for GI malignancies with varying expression levels of CDH17. Further, pharmacokinetics, toxicity, and IND-enabling studies of BSI-721 are underway."

Preclinical • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CDH17